Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase I Trial of Lira-cel Ovarian Cancer CAR-T Therapy

Anixa Biosciences, Inc. announced updated positive survival observations from its ongoing Phase I clinical trial of liraltagene autoleucel, or lira-cel, a follicle-stimulating hormone receptor-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.